Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CD70 CAR-T cells(Chongqing Precision Biotech) in Lung Cancer: NCT07181720 Clinical Landscape Report 2026
28 September 2026
NCT07181720 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07178171 Clinical Landscape Report 2026
28 September 2026
NCT07178171 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DXC-014 in Advanced Malignant Solid Neoplasm: NCT07177937 Clinical Landscape Report 2026
28 September 2026
NCT07177937 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Belzutifan in Metastatic Clear Cell Renal Cell Carcinoma: NCT07179770 Clinical Landscape Report 2026
28 September 2026
NCT07179770 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Ipilimumab in Metastatic Renal Cell Carcinoma: NCT07188896 Clinical Landscape Report 2026
28 September 2026
NCT07188896 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NRM-823 in Ovarian Cancer: NCT07182149 Clinical Landscape Report 2026
28 September 2026
NCT07182149 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Melphalan in Uveal Melanoma: NCT07183852 Clinical Landscape Report 2026
28 September 2026
NCT07183852 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rocbrutinib in Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type: NCT07189065 Clinical Landscape Report 2026
28 September 2026
NCT07189065 clinical landscape for Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type: endpoints, sponsor, phase, geography, readouts, asset cont…
9 min read
Polatuzumab Vedotin-Piiq in High grade B-cell lymphoma: NCT07184788 Clinical Landscape Report 2026
28 September 2026
NCT07184788 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IMPT-314 in Non-Hodgkin's lymphoma refractory: NCT07188558 Clinical Landscape Report 2026
28 September 2026
NCT07188558 clinical landscape for Non-Hodgkin's lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Doxorubicin Hydrochloride liposomal in Ewing Sarcoma: NCT07194044 Clinical Landscape Report 2026
28 September 2026
NCT07194044 clinical landscape for Ewing Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Triple Negative Breast Cancer: NCT07188246 Clinical Landscape Report 2026
28 September 2026
NCT07188246 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.